All Articles

The return of a critical antibiotic after 14 years via a new, ultra-fast FDA pathway signals a major shift in U.S. industrial and health policy.

A tech-driven 'anti-CRO' and a clinical accelerator have joined forces. Can their integrated model finally fix the broken drug development pipeline?

Senzing's acquisition of Placekey is more than a merger; it’s a bid to create a universal data language. But can an open standard thrive under corporate rule?

Biomerica's regulatory win in Egypt is more than a market entry; it's a strategic move to disrupt healthcare with low-cost, rapid diagnostic tools.

The fintech firm launched multicurrency accounts that unify traditional money and stablecoins, aiming to disrupt global payments for businesses.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

A Delaware Supreme Court ruling revives a massive liability risk for Loews, extending a seven-year legal battle over its 2018 Boardwalk Pipelines deal.

byNordic Acquisition Corp. buys another month in its search for a Nordic tech merger, but each extension drains funds and tests investor patience.

Brink's new $750M share repurchase is more than a financial move; it’s a bold declaration that its digital transformation is generating serious cash.

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.

A new 24g wearable device promises clinic-grade laser therapy for just $99. Can its high-power science truly democratize healing, or is it just hype?

A third-generation family takeover, backed by Canada's BDC, positions a 70-year-old firm to accelerate innovation in the competitive medical imaging market.

Beyond the ad break: How TripleLift's focus on creative formats, global retail media partnerships, and AI is disrupting the programmatic advertising landscape.

Abeona Therapeutics' new treatment center for ZEVASKYN marks a strategic leap in gene therapy access, but what does it mean for patients and the market?

Impressive drill results from Lapon Canyon are turning heads, but the discovery of monzonite-hosted gold suggests a much larger story is unfolding.

With leadership buying shares and promising trial data for its novel cancer drug, MAIA Biotechnology is sending strong signals to investors. What's next?

Ghost Robotics' new arm gives its Vision 60 the power to act. This leap from seeing to doing has huge implications for industries from defense to healthcare.

With a new $6.5M investment, Double is tackling the accounting talent crisis with AI that empowers professionals, not replaces them. Here's why.

As lithium fire risks escalate, a small-cap firm's live EV burn demo in Houston draws industry giants, signaling a pivotal moment for safety tech.

As esports races toward a $7.5B market, specialized hardware is king. Inside ZOWIE's strategy to win the high-stakes game of competitive tech.